Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.04 USD | +0.57% | +0.57% | +3.07% |
May. 28 | Axogen, Inc. Announces the Opening of its Axogen Processing Center | CI |
May. 16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
Financials (USD)
Sales 2024 * | 179M | Sales 2025 * | 201M | Capitalization | 308M |
---|---|---|---|---|---|
Net income 2024 * | -18M | Net income 2025 * | 5M | EV / Sales 2024 * | 1.72 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.53 x |
P/E ratio 2024 * |
-17
x | P/E ratio 2025 * |
-528
x | Employees | 427 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.22% |
Latest transcript on AxoGen, Inc.
1 day | +0.57% | ||
1 week | +0.57% | ||
Current month | +3.07% | ||
1 month | +24.16% | ||
3 months | -22.30% | ||
6 months | -3.56% | ||
Current year | +3.07% |
Managers | Title | Age | Since |
---|---|---|---|
Karen Zaderej
CEO | Chief Executive Officer | 62 | 06-04-30 |
Nir Naor
DFI | Director of Finance/CFO | 49 | Dec. 05 |
Marc Began
CMP | Compliance Officer | 57 | 23-03-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Thomas
BRD | Director/Board Member | 68 | 20-09-29 |
Director/Board Member | 63 | 16-08-31 | |
John Johnson
BRD | Director/Board Member | 66 | 21-07-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 430 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 7.04 | +0.57% | 276,750 |
24-06-05 | 7 | +2.04% | 144,669 |
24-06-04 | 6.86 | +0.59% | 386,028 |
24-06-03 | 6.82 | -0.15% | 169,958 |
24-05-31 | 6.83 | -2.43% | 180,072 |
Delayed Quote Nasdaq, June 06, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.07% | 308M | |
+9.24% | 221B | |
+15.84% | 198B | |
+23.95% | 148B | |
+31.67% | 112B | |
+4.41% | 66.85B | |
+14.99% | 52.84B | |
+4.85% | 50.86B | |
-4.47% | 38.75B | |
-0.41% | 35.15B |
- Stock Market
- Equities
- AXGN Stock